Status:
WITHDRAWN
How Does Platelet Dose Impact Clinical Outcomes After PRP Treatment?
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Osteoarthritis, Knee
Eligibility:
All Genders
40-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine which platelet rich plasma (PRP) injection dosage provides the most improvement in a patient's knee pain level at 26 weeks post-injection.
Detailed Description
Knee osteoarthritis (OA) is a chronic progressive disease affecting more than 20% of people older than 45 years. A myriad of different treatments have been proposed in the scientific literature, and c...
Eligibility Criteria
Inclusion
- 40-80 years of age
- Previous diagnosis of unilateral, primary osteoarthritis of the knee
- Knee pain; duration of symptoms \> 4 weeks
- K-L grade 0-4
Exclusion
- Under 40 years of age; over 80 years of age
- Bilateral knee pain
- Duration of symptoms \< 4 weeks
- NSAID or clopidogrel use in the last 7 days
- High risk of a thrombotic event if discontinuing NSAID or clopidogrel for four weeks.
- Steroid use in the last 6 weeks
- Active diagnosis of leukopenia/anemia/thrombocytopenia
Key Trial Info
Start Date :
March 6 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 7 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05330689
Start Date
March 6 2022
End Date
September 7 2022
Last Update
March 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232